Sebastian Reinstadler

Dr. Sebastian Reinstadler

University Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2020 in European Heart Journal
Verified
Journal Article
Open access
PDF file
BMBernhard Metzler
Bernhard Metzler
PSPeter Siostrzonek
Peter Siostrzonek
RBRonald Binder
Ronald Binder
ABAxel Bauer
Axel Bauer
SRSebastian Reinstadler
Sebastian Reinstadler
We conducted a nationwide retrospective survey on the impact of COVID-19 on the diagnosis and treatment of acute cornary syndrome (ACS) from 2 to 29 March in Austria.

20 May 2024 in JACC
Verified
Journal Article
Closed access
ILIvan Lechner
Ivan Lechner
MRMartin Reindl
Martin Reindl
TSThomas Stiermaier
Thomas Stiermaier
CTChristina Tiller
Christina Tiller
MHMagdalena Holzknecht
Magdalena Holzknecht
SRSebastian Reinstadler
Sebastian Reinstadler

23 March 2023 in European Heart Journal - Digital Health
Verified
Journal Article
Open access
PDF file
FTFabian Theurl
Fabian Theurl
MSMichael Schreinlechner
Michael Schreinlechner
NSNikolay Sappler
Nikolay Sappler
MTMichael Toifl
Michael Toifl
TDTheresa Dolejsi
Theresa Dolejsi
ABAxel Bauer
Axel Bauer
We aimed to investigate the concordance between heart rate variability (HRV) derived from the PPG signal of a commercially available smartwatch compared to gold-standard high-resolution ECG derived HRV in patients with cardiovascular disease. We prospectively enrolled 104 survivors of acute ST-elevation myocardial infarction, 129 patients after ischemic stroke and 30 controls. All subjects underwent simultaneous recording of a smartwatch (Garmin vivoactive 4, Garmin Ltd., Olathe, USA) derived PPG signal and a high-resolution (1000Hz) ECG for 30 minutes under standardized conditions. HRV measures in time and frequency domain, non-linear measures as well as deceleration capacity (DC) were calculated according to previously published technologies from both signals. Lin’s concordance correlation coefficient (ρc) between smartwatch derived and ECG based HRV markers was used as measure of diagnostic accuracy. Very high concordance within the whole study cohort was observed for mean heart rate (ρc=0.9998), standard deviation of the averages of normal-to-normal (NN) intervals in all 5-minute segments (SDANN; ρc=0.9617) and very low frequency power (VLF power; ρc=0.9613). Detrended fluctuation analysis (DF-α1; ρc=0.5919) and square mean root of the sum of squares of adjacent NN-interval differences (rMSSD; ρc=0.6617) on the contrary showed only moderate concordance. Smartwatch derived HRV provides a practical alternative with excellent accuracy compared to ECG based HRV for global markers and those characterizing lower frequency components. However, caution is warranted with HRV markers that predominantly assess short-term variability.

11 October 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
ILIvan Lechner
Ivan Lechner
MRMartin Reindl
Martin Reindl
CTChristina Tiller
Christina Tiller
MHMagdalena Holzknecht
Magdalena Holzknecht
FTFelix Troger
Felix Troger
SRSebastian Reinstadler
Sebastian Reinstadler
The severity of myocardial tissue damage following ST-elevation myocardial infarction (STEMI) strongly determines short- and long-term prognosis. This study explored the impact of the coronavirus disease 2019 (COVID-19) pandemic and associated public health restrictions on infarct severity. STEMI patients treated with primary percutaneous coronary intervention (PCI) and included in the prospective Magnetic Resonance Imaging in Acute ST-Elevation Myocardial Infarction (MARINA-STEMI) cohort study from 2015- 2020 (n = 474) were categorized according to (i) timeframes with and without major public health restrictions in 2020, and (ii) timeframes of major public health restrictions during 2020 and during the corresponding timeframes between 2015-2019. Myocardial damage was evaluated by cardiac magnetic resonance imaging. During major public health restrictions in 2020 (n = 48), there was an increase in infarct size (22 [IQR 12-29] vs. 14 [IQR 6-23]%, P < 0.01), a higher frequency (77% vs. 52%, P < 0.01) and larger extent of microvascular obstruction (1.5 [IQR 0.1-11.4] vs. 0.2 [IQR 0.0-2.6]%, P < 0.01) and a higher rate of intramyocardial haemorrhage (56% vs. 34%, P = 0.02) as compared to the phases without major restrictions in 2020 (n = 101). These findings were confirmed in adjusted analysis and were consistent when comparing patients admitted in 2020 versus patients admitted in the “pre-pandemic” era (2015-2019). Patient characteristics were comparable between groups, except for a significantly longer total ischemia time (P < 0.01) and higher frequency of pre-PCI Thrombolysis in Myocardial Infarction (TIMI) flow 0 during times of major restrictions (P = 0.03). This study provides novel mechanistic insights demonstrating a significant increase in myocardial damage in STEMI patients admitted during the COVID-19 pandemic with a temporal relation to major public health restrictions.

Verified
Journal Article
Open access
PDF file
MRMartin Reindl
Martin Reindl
IEIngo Eitel
Ingo Eitel
SRSebastian Reinstadler
Sebastian Reinstadler
Cardiac magnetic resonance (CMR) imaging allows comprehensive assessment of myocardial function and tissue characterization in a single examination after acute ST-elevation myocardial infarction. Markers of myocardial infarct severity determined by CMR imaging, especially infarct size and microvascular obstruction, strongly predict recurrent cardiovascular events and mortality. The prognostic information provided by a comprehensive CMR analysis is incremental to conventional risk factors including left ventricular ejection fraction. As such, CMR parameters of myocardial tissue damage are increasingly recognized for optimized risk stratification to further ameliorate the burden of recurrent cardiovascular events in this population. In this review, we provide an overview of the current impact of CMR imaging on optimized risk assessment soon after acute ST-elevation myocardial infarction.

Verified
Journal Article
Open access
PDF file
SRSebastian Reinstadler
Sebastian Reinstadler
MRMartin Reindl
Martin Reindl
ILIvan Lechner
Ivan Lechner
MHMagdalena Holzknecht
Magdalena Holzknecht
CTChristina Tiller
Christina Tiller
BMBernhard Metzler
Bernhard Metzler
Coronavirus disease 19 (COVID-19) and its associated restrictions could affect ischemic times in patients with ST-segment elevation myocardial infarction (STEMI). The objective of this study was to investigate the influence of the COVID-19 outbreak on ischemic times in consecutive all-comer STEMI patients. We included consecutive STEMI patients (n = 163, median age: 61 years, 27% women) who were referred to seven tertiary care hospitals across Austria for primary percutaneous coronary intervention between 24 February 2020 (calendar week 9) and 5 April 2020 (calendar week 14). The number of patients, total ischemic times and door-to-balloon times in temporal relation to COVID-19-related restrictions and infection rates were analyzed. While rates of STEMI admissions decreased (calendar week 9/10 (n = 69, 42%); calendar week 11/12 (n = 51, 31%); calendar week 13/14 (n = 43, 26%)), total ischemic times increased from 164 (interquartile range (IQR): 107–281) min (calendar week 9/10) to 237 (IQR: 141–560) min (calendar week 11/12) and to 275 (IQR: 170–590) min (calendar week 13/14) (p = 0.006). Door-to-balloon times were constant (p = 0.60). There was a significant difference in post-interventional Thrombolysis in myocardial infarction (TIMI) flow grade 3 in patients treated during calendar week 9/10 (97%), 11/12 (84%) and 13/14 (81%; p = 0.02). Rates of in-hospital death and re-infarction were similar between groups (p = 0.48). Results were comparable when dichotomizing data on 10 March and 16 March 2020, when official restrictions were executed. In this cohort of all-comer STEMI patients, we observed a 1.7-fold increase in ischemic time during the outbreak of COVID-19 in Austria. Patient-related factors likely explain most of this increase. Counteractive steps are needed to prevent further cardiac collateral damage during the ongoing COVID-19 pandemic.